Skip to textbook content
Doctor’s PassportTextbook
TopicsAll topics

Loading topic navigation…

Textbook navigation
TopicsAll topics

Loading topic navigation…
← Respiratory indexChapter sections
Purpose and principlesIndications, selection and cautionsAssessment before treatmentTreatment approachRegimens, contraindications and interactionsComplications, monitoring and follow-upSpecial situationsCommon pitfallsQuestionsSources
Full textbook10 sectionsOpen only what you need
Educational draft · awaiting clinical reviewThe full textbook explains uncertainty but does not replace live national or local guidance, specialist advice, or current prescribing information.

Treatment of pulmonary embolism

Respiratory · UK scope · Sources checked 27 Aug 2026 · Clinical review pending

RapidFull
!
Time-critical presentation

Any confirmed or suspected PE with cardiac arrest, shock, persistent hypotension, worsening perfusion or rapidly deteriorating oxygenation leaves the routine anticoagulation pathway and requires immediate high-risk PE/reperfusion assessment.

Purpose and principles

Treat confirmed haemodynamically stable PE with the right anticoagulant, dose, duration and follow-up plan while recognising patients who need admission, a different drug strategy or urgent escalation.

Anticoagulants prevent extension and recurrence; they do not instantly dissolve the embolus. Clinical recovery depends on endogenous fibrinolysis, cardiopulmonary reserve and supportive care.

Drug choice is inseparable from dosing sequence. Omitting the apixaban 7-day or rivaroxaban 21-day loading phase under-treats acute VTE; continuing it too long increases bleeding.

The three-month review is a new treatment decision, not an automatic stop date. Provoked versus unprovoked disease and bleeding risk guide the balance.

Inferior vena caval filters are not routine adjuncts. NICE reserves them mainly for a proximal DVT/PE when anticoagulation is contraindicated, or selected treatment failure after specialist review; establish removal plans early.

Key points

  • For confirmed proximal DVT or PE, NICE recommends therapeutic anticoagulation for at least 3 months.
  • For most haemodynamically stable adults, offer apixaban or rivaroxaban if suitable; each has a mandatory higher-dose initial phase.
  • Apixaban: 10 mg twice daily for 7 days, then 5 mg twice daily. Rivaroxaban: 15 mg twice daily for 21 days, then 20 mg once daily with food.
  • If apixaban and rivaroxaban are unsuitable, options include LMWH for at least 5 days followed by dabigatran or edoxaban, or LMWH/UFH overlapped with a vitamin K antagonist until the INR is therapeutic.
  • Before selection, check active bleeding, FBC/platelets, renal and liver function, pregnancy possibility, body weight, cancer site, antiphospholipid syndrome, interacting medicines and ability to adhere.
  • Use a validated low-risk tool plus clinical judgement when considering outpatient treatment; social support, bleeding risk, comorbidity, oxygen need and reliable follow-up also matter.
  • At 3 months review whether the PE was provoked, whether the provoking factor has resolved, recurrence risk, bleeding risk and patient preference.

Indications, selection and cautions

Stable PE suitable for anticoagulation

Normal perfusion, no shock or persistent hypotension, manageable oxygen requirement and no immediate reperfusion indication. Severity and outpatient suitability still require assessment.

Bleeding or anticoagulant contraindicationRed flag

Active major bleeding, recent high-risk surgery, severe thrombocytopenia, intracranial pathology or another major haemorrhage risk requires senior haematology/specialty discussion and sometimes a temporary IVC filter.

Cancer-associated thrombosis

Active cancer raises recurrence and bleeding risks; gastrointestinal/genitourinary lesions and anticancer-drug interactions can shift choice away from a DOAC.

Antiphospholipid syndrome

Known triple-positive APS or arterial thrombosis changes the long-term strategy toward LMWH bridging and a vitamin K antagonist rather than a DOAC.

Deterioration on treatmentRed flag

New hypotension, syncope, rising lactate, increasing oxygen need or chest pain demands immediate reassessment for high-risk PE, bleeding, recurrent embolism or an alternative diagnosis.

Assessment before treatment

  1. 01
    FBC and platelet countFirst step
    Why
    Identify anaemia, thrombocytopenia and a baseline for bleeding/HIT surveillance.
    Interpretation and limitations
    A falling haemoglobin suggests occult bleeding; a major platelet fall after heparin exposure requires urgent HIT assessment.
  2. 02
    Creatinine and calculated creatinine clearance
    Why
    Select and dose anticoagulation safely.
    Interpretation and limitations
    Use Cockcroft–Gault creatinine clearance where the product information specifies it; eGFR and CrCl are not interchangeable at extremes.
  3. 03
    Liver function and coagulation screen
    Why
    Identify hepatic disease/coagulopathy and establish a baseline.
    Interpretation and limitations
    Significant hepatic disease with coagulopathy may make DOAC treatment unsuitable; PT/APTT do not quantify routine DOAC intensity.
  4. 04
    Weight, pregnancy status and medicines reconciliation
    Why
    Detect groups needing an alternative agent, dose or specialist advice.
    Interpretation and limitations
    Record actual weight; examine strong CYP3A4/P-gp interactions, antiplatelets, NSAIDs and hormonal therapy.
  5. 05

Treatment approach

01First lineStable confirmed PE in most adultsFirst stepFirst lineConfirmed PE, haemodynamically stable, no major contraindication and apixaban/rivaroxaban suitable.+
  1. 1Document baseline FBC, renal/liver function, coagulation, weight, bleeding risk, interactions and pregnancy status where relevant.
  2. 2Start either apixaban 10 mg twice daily for 7 days then 5 mg twice daily, or rivaroxaban 15 mg twice daily for 21 days then 20 mg once daily with food; prescribe the transition date explicitly.
  3. 3Decide admission versus outpatient care using a validated risk tool plus clinical/social criteria and provide anticoagulant counselling, written bleeding advice and contact details.
  4. 4

Regimens, contraindications and interactions

NICE first-line oral option for most stable confirmed PE when suitable.

Apixaban

10 mg orally twice daily for 7 days, then 5 mg twice daily; if extended prevention is chosen after 6 months, the licensed prevention dose is 2.5 mg twice daily.

Active bleeding, significant hepatic coagulopathy, interacting strong CYP3A4/P-gp drugs and pregnancy. Check current SmPC for renal and peri-procedural advice; the AF dose-reduction rule must not be copied into acute VTE treatment.

NICE first-line oral option for most stable confirmed PE when suitable.

Rivaroxaban

15 mg orally twice daily with food for 21 days, then 20 mg once daily with food; after at least 6 months, 10 mg once daily is licensed for extended prevention, with 20 mg considered when recurrence risk is high.

Active bleeding, significant liver disease/coagulopathy, renal impairment and interacting drugs. The 15 mg and 20 mg doses must be taken with food; document the day-22 switch.

Initial/alternative therapy, including bridging or situations where an oral agent is unsuitable.

Enoxaparin

For symptomatic PE, 1 mg/kg subcutaneously every 12 hours is a commonly licensed treatment regimen; a once-daily regimen is reserved for selected uncomplicated lower-risk patients under the SmPC.

Renal impairment, HIT history, thrombocytopenia, extreme weight and neuraxial procedures. Use an agent-specific renal regimen and consider anti-Xa advice in complex patients.

Complications, monitoring and follow-up

  • At initiation, document FBC, platelets, renal/liver function, weight, interactions, bleeding risk and exact high-dose-to-maintenance transition date.
  • Contact/review early to check adherence, bleeding, recurrent symptoms and that the dose transition occurred correctly.
  • Repeat FBC and renal/liver function according to clinical risk and at least during regular long-term review; monitor more often in frailty, renal change or intercurrent illness.
  • At 3 months, record the provoked/unprovoked classification, resolved or persistent risk factor, recurrence/bleeding balance and shared duration decision.
  • After PE, investigate persistent dyspnoea, exercise limitation, syncope or signs of pulmonary hypertension rather than attributing every symptom to deconditioning.
  • Provide written advice on missed doses, bleeding, procedures, pregnancy and when to seek urgent help; ensure all clinicians know the anticoagulant and last dose.

Special situations

Acute VTE dosing is indication-specific

Apixaban dose reduction used in atrial fibrillation does not define acute PE dosing. Always select the product's VTE regimen.

Two DOACs are single-drug pathways

Apixaban and rivaroxaban include their own oral loading phase; dabigatran and edoxaban require preceding parenteral anticoagulation.

Outpatient does not mean low-governance

Ambulatory PE needs prompt drug supply, education, reliable contact, review and a route back if symptoms worsen.

The trigger matters more than residual clot

Duration decisions are usually based on recurrence and bleeding risk, not routine repeat CTPA to prove clot disappearance.

IVC filters solve a narrow problem

They do not treat the existing embolus and create thrombosis/retrieval risks; use only for a defined indication with an early removal strategy.

Common pitfalls

  1. 01

    Prescribing the maintenance DOAC dose from day 1 and omitting the acute loading phase.

  2. 02

    Using an atrial-fibrillation apixaban dose-reduction rule for acute VTE.

  3. 03

    Calling a patient outpatient-suitable from a score without assessing oxygen, bleeding, renal function, adherence and support.

  4. 04

    Stopping all provoked and continuing all unprovoked PE without an individual bleeding/recurrence discussion.

  5. 05

    Using a DOAC routinely in triple-positive APS.

  6. 06

    Ordering routine repeat CTPA to decide whether anticoagulation can stop.

Practice

Two practice questions

Your practice draft is saved in this browser.

Question 1 of 2
0 correct
RespiratoryOriginal SBA

Haemodynamically unstable pulmonary embolism

A patient with confirmed pulmonary embolism develops persistent systolic blood pressure of 78 mmHg with cool peripheries and confusion. There is no major bleeding contraindication. Which immediate treatment approach best matches NICE guidance?

Choose one answer, then submit
← Rapid synopsisBack to overviewAll Respiratory topics →
Sources and review status5 sources · checked 27 Aug 2026 · clinical review pending+
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.

  • NICE NG158: Venous thromboembolic diseases—recommendationsFirst-line selection, at least 3 months' treatment, special populations and review.
  • Eliquis 5 mg SmPCCurrent licensed apixaban VTE dosing and cautions.
  • Xarelto 20 mg SmPCCurrent licensed rivaroxaban VTE dosing and extended prevention.
  • Clexane SmPCLicensed enoxaparin treatment dosing and safety information.
  • Pradaxa 150 mg SmPCDabigatran VTE regimen after parenteral anticoagulation.

Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem · Content changes

Authoring stateComplete draftClinical stateAwaiting reviewJurisdictionUnited Kingdom
  • Consider stopping after 3 months for a provoked PE with a resolved provoking factor and an uncomplicated course; consider continuing beyond 3 months after unprovoked PE when recurrence risk outweighs bleeding risk.
  • Active cancer usually requires 3–6 months of treatment followed by reassessment; tumour site, drug interactions and bleeding risk determine whether a DOAC or LMWH is preferred.
  • Triple-positive antiphospholipid syndrome is a vitamin K antagonist pathway, not routine DOAC treatment.
    • Clinical severity and validated outpatient-risk assessment
    Why
    Choose inpatient versus ambulatory care.
    Interpretation and limitations
    A low-risk score is necessary but not sufficient: oxygen requirement, bleeding, renal failure, pain, pregnancy, adherence and home support can still mandate admission.
  • 06
    Cancer and provoking-factor review
    Why
    Determine duration, recurrence risk and need for further investigation.
    Interpretation and limitations
    Use history, examination and routine age-appropriate assessment; do not perform indiscriminate extensive occult-cancer imaging without symptoms or signs.
  • 07
    Three-month treatment review
    Why
    Reassess benefit versus bleeding and confirm the ongoing dose.
    Interpretation and limitations
    Resolved major transient factor favours stopping; unprovoked, persistent risk or recurrence favours extended therapy if bleeding risk is acceptable.
    • Arrange a three-month review before the prescription expires; do not leave duration implicit.
    02AlternativeDOAC loading strategy unsuitableAlternativeApixaban/rivaroxaban contraindicated, unsuitable or declined.+
    1. 1Give therapeutic LMWH for at least 5 days, then start dabigatran or edoxaban if suitable; alternatively overlap LMWH/UFH with a vitamin K antagonist.
    2. 2For a vitamin K antagonist, continue parenteral anticoagulation for at least 5 days and until INR is at least 2.0 on 2 consecutive readings, then maintain the agreed INR target.
    3. 3Seek specialist input for severe renal impairment, extreme body weight, pregnancy, breastfeeding, significant liver disease, thrombocytopenia, APS or complex interactions.
    03DurationDecision at three monthsCompletion of the initial 3 months of therapeutic anticoagulation.+
    1. 1Confirm adherence, bleeding events, residual symptoms and whether the event was provoked by a now-resolved major transient factor.
    2. 2Provoked and uncomplicated with factor resolved: consider stopping. Unprovoked or persistent risk: discuss continued anticoagulation, recurrence risk, bleeding risk and preference.
    3. 3If continuing, verify the licensed extended-treatment dose and review at least annually or sooner when renal function, weight, cancer treatment or bleeding risk changes.
    04Cancer/APSHigh-complexity selectionActive cancer or known triple-positive antiphospholipid syndrome.+
    1. 1Cancer: consider tumour site, bleeding risk, renal function and anticancer-drug interactions; agree DOAC versus LMWH with oncology/haematology and review at 3–6 months.
    2. 2Triple-positive APS: use LMWH initially and transition to a vitamin K antagonist under specialist guidance; avoid routine DOAC substitution.
    3. 3Recurrent VTE despite apparently therapeutic treatment: confirm adherence/dosing, investigate interactions and recurrence, and seek specialist advice rather than simply adding antiplatelet therapy.
    Oral alternative when apixaban/rivaroxaban are unsuitable but a DOAC remains appropriate.

    Dabigatran

    150 mg orally twice daily only after at least 5 days of therapeutic parenteral anticoagulation; licensed reductions/avoidance depend on age, renal function and interacting medicines.

    Do not start as a single-drug acute loading regimen. Check creatinine clearance, age, verapamil and bleeding risk against the current SmPC.

    Option when DOACs are unsuitable and preferred for triple-positive APS.

    Warfarin

    Individualised loading with INR monitoring; overlap therapeutic LMWH/UFH for at least 5 days and until INR is at least 2.0 on 2 consecutive readings. Typical VTE target INR is 2.5 (range 2.0–3.0).

    Major food/drug interactions, pregnancy teratogenicity and narrow therapeutic range. Never use a fixed maintenance dose without INR-led titration.